<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Identification of methylation-silenced genes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is of great importance </plain></SENT>
<SENT sid="1" pm="."><plain>We employed oligonucleotide microarrays to identify differences in global gene expression of five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines (HCT116, RKO, Colo320, SW480 and HT29) that were analyzed before and after treatment with 5-aza-2'-deoxycitidine </plain></SENT>
<SENT sid="2" pm="."><plain>Selected candidates were subjected to methylation-specific PCR and real-time quantitative reverse transcription-PCR using 15 CRC cell lines and 23 paired <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> samples from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>After 5-aza-2'-deoxycitidine treatment, 139 genes were re-expressed in <z:hpo ids='HP_0000001'>all</z:hpo> 5 CRC cell lines collectively with a fold change of more than 1.5 in at least one cell line </plain></SENT>
<SENT sid="4" pm="."><plain>These genes include known methylated and silenced genes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>After applying study selection criteria we identified 20 candidates </plain></SENT>
<SENT sid="6" pm="."><plain>The GADD45B and THSD1 genes were selected for further analysis </plain></SENT>
<SENT sid="7" pm="."><plain>Among 15 <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines, methylation was only identified in THSD1 (27%) </plain></SENT>
<SENT sid="8" pm="."><plain>THSD1 methylation was subsequently investigated in 23 colorectal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and methylation was detected in 9% of the analyzed samples; the observed promoter hypermethylation was <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific </plain></SENT>
<SENT sid="9" pm="."><plain>THSD1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> down-regulation was observed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="10" pm="."><plain>This genome-wide screening led to the identification of genes putatively affected by methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The THSD1 gene may play a role in the <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>